Published in Lancet Neurol on July 01, 2010
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med (2011) 1.52
A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med (2014) 1.51
Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation. ACS Chem Neurosci (2012) 1.43
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Transcriptional data: a new gateway to drug repositioning? Drug Discov Today (2012) 1.40
The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care. Alzheimers Res Ther (2016) 1.39
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One (2011) 1.23
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Using genetics to enable studies on the prevention of Alzheimer's disease. Clin Pharmacol Ther (2012) 1.14
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep (2012) 1.12
Amyloid-ß-directed immunotherapy for Alzheimer's disease. J Intern Med (2014) 1.04
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem (2013) 1.04
Brain investigation and brain conceptualization. Funct Neurol (2013) 1.03
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging (2012) 1.02
Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience (2014) 1.01
Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease. Cell Mol Life Sci (2014) 1.01
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss. Proc Natl Acad Sci U S A (2012) 1.01
Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp Neurol (2012) 0.99
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.99
Neural tissue engineering using embryonic and induced pluripotent stem cells. Stem Cell Res Ther (2011) 0.99
Epigenetic memory: the Lamarckian brain. EMBO J (2014) 0.99
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries. Front Pharmacol (2014) 0.98
Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model. Nat Commun (2014) 0.98
Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res (2015) 0.95
Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radic Biol Med (2016) 0.95
Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. J Neurosci (2014) 0.94
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry (2013) 0.94
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther (2014) 0.93
Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol (2011) 0.93
γ-Secretase associated with lipid rafts: multiple interactive pathways in the stepwise processing of β-carboxyl-terminal fragment. J Biol Chem (2013) 0.92
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci (2013) 0.92
Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther (2013) 0.92
Alzheimer's-related peptide amyloid-β plays a conserved role in angiogenesis. PLoS One (2012) 0.92
Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Next generation therapeutics for Alzheimer's disease. EMBO Mol Med (2013) 0.91
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci (2011) 0.91
Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J Neurosci (2015) 0.91
For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther (2011) 0.91
Dementia: is the biopsychosocial model vindicated? Br J Gen Pract (2017) 0.90
A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease. PLoS One (2013) 0.90
Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain Disord Ther (2012) 0.89
Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep (2014) 0.89
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. Front Physiol (2012) 0.89
In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders. PLoS One (2014) 0.89
Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) (2013) 0.88
p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease. Mol Psychiatry (2015) 0.88
Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptides. Proc Natl Acad Sci U S A (2012) 0.88
A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol (2011) 0.87
Amyloid precursor proteins interact with the heterotrimeric G protein Go in the control of neuronal migration. J Neurosci (2013) 0.87
Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic review. Dement Geriatr Cogn Dis Extra (2012) 0.87
Rodent models of neuroinflammation for Alzheimer's disease. J Neuroinflammation (2015) 0.87
Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. Brain Connect (2014) 0.86
Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am J Nucl Med Mol Imaging (2012) 0.85
Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: an early event in disease pathogenesis. J Neurochem (2013) 0.85
Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging (2013) 0.84
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging (2013) 0.84
Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov (2016) 0.83
Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front Behav Neurosci (2014) 0.83
Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease. PLoS One (2013) 0.83
High resolution imaging study of interactions between the 37 kDa/67 kDa laminin receptor and APP, beta-secretase and gamma-secretase in Alzheimer's disease. PLoS One (2014) 0.83
Drug development status for Alzheimer's disease: present scenario. Neurol Sci (2013) 0.83
Alzheimer disease: biomarker trajectories across stages of Alzheimer disease. Nat Rev Neurol (2012) 0.83
Somatic comorbidities and Alzheimer's disease treatment. Neurol Sci (2013) 0.83
SCM-198 inhibits microglial overactivation and attenuates Aβ(1-40)-induced cognitive impairments in rats via JNK and NF-кB pathways. J Neuroinflammation (2014) 0.83
New treatment strategies for Alzheimer's disease: is there a hope? Indian J Med Res (2013) 0.82
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther (2011) 0.82
Drug development for Alzheimer's disease: recent progress. Exp Neurobiol (2010) 0.82
Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One (2013) 0.82
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther (2014) 0.82
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease. J Neuroimmunol (2014) 0.82
Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer's Disease. Curr Neuropharmacol (2014) 0.81
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease. J Cell Mol Med (2016) 0.81
Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J Med Chem (2012) 0.81
Insight of the cytotoxicity of the aggregates of peptides or aberrant proteins: a meta-analysis. PLoS One (2014) 0.81
Prevention strategies for Alzheimer's disease. Transl Neurodegener (2012) 0.81
Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models. Curr Pharm Des (2014) 0.81
Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. Mol Neurodegener (2015) 0.81
Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. Acta Neuropathol (2015) 0.80
Epigenetics of Alzheimer's disease and frontotemporal dementia. Neurotherapeutics (2013) 0.80
Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimers Res Ther (2014) 0.80
Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time. Dement Geriatr Cogn Dis Extra (2012) 0.80
Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level. Sci Rep (2016) 0.79
Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J Diabetes Investig (2011) 0.79
Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) (2016) 0.79
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci (2014) 0.79
A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging (2014) 0.79
Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy. J Neuroimmunol (2014) 0.79
Histone-acetylation: a link between Alzheimer's disease and post-traumatic stress disorder? Front Neurosci (2014) 0.79
Neuritogenic monoglyceride derived from the constituent of a marine fish for activating the PI3K/ERK/CREB signalling pathways in PC12 cells. Int J Mol Sci (2013) 0.79
Mild cognitive impairment. Lancet (2006) 10.21
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol (2004) 5.78
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol (2006) 4.54
The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol (2005) 4.54
Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol (2005) 4.49
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ (2010) 3.98
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol (2005) 3.95
Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol (2002) 3.70
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
The worldwide economic impact of dementia 2010. Alzheimers Dement (2013) 3.23
The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord (2003) 3.23
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology (2013) 3.20
Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med (2006) 2.90
Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden. Am J Public Health (2008) 2.86
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci (2009) 2.86
The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement (2010) 2.75
Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke (2003) 2.60
Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc (2009) 2.54
Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging (2004) 2.49
Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord (2010) 2.49
Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol (2004) 2.35
The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A (2008) 2.30
Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab (2003) 2.27
Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord (2005) 2.19
The Stroke Riskometer(TM) App: validation of a data collection tool and stroke risk predictor. Int J Stroke (2014) 2.18
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J (2013) 2.15
Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord (2004) 2.12
Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med (2010) 2.04
Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ (2009) 2.00
Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. J Am Geriatr Soc (2007) 1.92
Person-centred care of people with severe Alzheimer's disease: current status and ways forward. Lancet Neurol (2008) 1.86
An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement (2007) 1.83
A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clin Exp Res (2004) 1.78
Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry (2008) 1.77
Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol (2004) 1.72
BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem (2008) 1.68
Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging (2006) 1.65
Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ (2003) 1.65
Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc (2007) 1.65
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Potential markers of oxidative stress in stroke. Free Radic Biol Med (2005) 1.63
Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am Geriatr Soc (2003) 1.62
The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes (2007) 1.62
Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord (2009) 1.58
Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology (2013) 1.55
Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry (2002) 1.55
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J (2005) 1.54
Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem (2003) 1.54
Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2009) 1.53
Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr (2008) 1.53
A nine-transmembrane domain topology for presenilin 1. J Biol Chem (2005) 1.52
Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. Glia (2007) 1.51
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ (2004) 1.51
Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res (2003) 1.50
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry (2008) 1.49
Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem (2009) 1.48
Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry (2006) 1.47
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44
Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis (2009) 1.43
MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol Aging (2006) 1.41
[Genetics of Alzheimer's disease]. Duodecim (2004) 1.40
Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem (2004) 1.39
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol (2003) 1.36
APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol (2004) 1.36
Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol (2002) 1.36
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord (2006) 1.35
Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol (2002) 1.34
Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage (2011) 1.34
Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol (2003) 1.33
Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage (2007) 1.33
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther (2010) 1.30
AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci (2009) 1.30
The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer's disease risk: a prospective cohort study. J Alzheimers Dis (2011) 1.30
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord (2006) 1.28
MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci (2009) 1.28
Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res (2002) 1.27
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
Mild cognitive impairment: a systematic review. J Alzheimers Dis (2007) 1.25
Carotid intima-media thickness and cognitive function in elderly women: a population-based study. Neuroepidemiology (2007) 1.25
AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage (2011) 1.24
APOE-related mortality: effect of dementia, cardiovascular disease and gender. Neurobiol Aging (2008) 1.23
Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry (2014) 1.21
Elderly patients with cognitive impairment have a high risk for functional decline during hospitalization: The GIFA Study. J Gerontol A Biol Sci Med Sci (2005) 1.20
The impact of somatic and cognitive disorders on the functional status of the elderly. J Clin Epidemiol (2002) 1.20